Compounded Semaglutide: What It Is, Whether It's Legal, and What It Costs
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency.
You have probably read two very different takes on compounded GLP-1 medications. One side says they are a smart, lower-cost option compared with brand-name drugs. The other says they are unregulated, dangerous, and illegal. Neither version is the full story.
The factual answer requires understanding what compounding pharmacies are, what federal law allows them to do, why GLP-1 compounding became widely available when it did, and what the current regulatory picture looks like after two major drugs came off the FDA shortage list. This page covers all of that.
One thing to be clear about upfront: Compounded medications are not FDA-approved products. They have not been reviewed by the FDA for safety, efficacy, or quality. This is not a technicality or fine print. It is a meaningful distinction that should factor into any decision you make. We will say it more than once on this page because it matters.
Ready to start? Pick your medication
If you have already done your research, you do not need to reread the regulatory history. Pick the medication you are interested in and read the step-by-step guide:
- How to get compounded semaglutide - offered by some programs as a weekly injection or a daily oral option
- How to get compounded tirzepatide - usually offered as a weekly injection
Not sure which one fits your situation? That is a question for a licensed provider, who can review your health history and decide which medication and dose, if any, is clinically appropriate for you. What drives the cost is covered later on this page.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedStill researching? Good. The rest of this page covers what you should know before trusting any compounded GLP-1 source.
What compounding pharmacies are and what they do
Pharmaceutical compounding is the practice of preparing a medication specifically for an individual patient, outside the standard manufacturing process used to produce commercially available drugs. Compounding pharmacies have existed for most of the history of modern medicine. Before pharmaceutical manufacturing became industrialized, most medications were compounded by pharmacists.
Today, compounding pharmacies are most commonly used in situations where:
- A patient needs a specific dose that is not available in a commercially manufactured form
- A patient cannot tolerate an ingredient (a dye, a preservative, a filler) in the commercial version
- A medication has been discontinued and no commercial source exists
- A patient needs a different delivery format than the commercial version provides
Federal law regulates compounding pharmacies through the Drug Quality and Security Act of 2013, which created two regulatory categories: 503A pharmacies and 503B outsourcing facilities.
503A vs. 503B: what the distinction means
Understanding the difference between these two categories matters for evaluating the compounding pharmacy your medication comes from.
503A pharmacies are traditional, patient-specific compounding pharmacies. They are licensed by state pharmacy boards. They can only compound medications based on a valid, individual patient prescription from a licensed prescriber. They cannot produce medications in bulk or distribute to healthcare facilities without patient-specific orders. 503A pharmacies are not FDA-registered and are not subject to federal Current Good Manufacturing Practice (CGMP) standards, though state pharmacy boards set their own standards.
503B outsourcing facilities are a category created by the 2013 federal law. They are FDA-registered, subject to CGMP standards, and can compound medications in larger batches without patient-specific prescriptions. They can distribute to healthcare facilities. Because they are FDA-registered and CGMP-compliant, they face a higher and more uniform regulatory bar than 503A pharmacies.
For a deeper comparison, see our dedicated page: 503A vs. 503B compounding pharmacies explained.
Neither 503A nor 503B pharmacies produce FDA-approved medications. FDA registration (for 503B) is not the same as FDA approval of the compounded product. That distinction is critical and frequently misrepresented in GLP-1 marketing.
How FDA drug shortages created the legal basis for GLP-1 compounding
Federal law limits compounders from making copies of commercially available, FDA-approved drugs, but a drug on the FDA’s official drug shortage list is treated differently. The relevant provisions are section 503A(b)(1)(D) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) for 503A pharmacies and section 503B(a)(2)(A) (21 U.S.C. 353b) for 503B outsourcing facilities.
The FDA maintains the drug shortage list based on reports from manufacturers and healthcare providers. When a drug is listed, it signals that commercial supply is insufficient to meet patient demand.
Semaglutide injection products were on the FDA drug shortage list, which gave compounding pharmacies room to prepare compounded semaglutide for patients. This is the legal foundation that allowed GLP-1 compounding to scale from small-scale traditional pharmacy use to a significant market segment.
Tirzepatide injection products were also on the shortage list during a period of high demand and constrained supply.
Both shortages have since been resolved, according to the FDA[1]:
- Tirzepatide. The FDA first determined the tirzepatide injection shortage was resolved on October 2, 2024, and reissued that decision on December 19, 2024. The FDA said its period of enforcement discretion for 503A pharmacies ended after a court denied a preliminary injunction on March 5, 2025, and for 503B outsourcing facilities on March 19, 2025.
- Semaglutide. On February 21, 2025, the FDA determined the semaglutide injection shortage was resolved. The FDA said its 503A period ended after an April 24, 2025 court decision denied a preliminary injunction in Outsourcing Facilities Association v. FDA (the original end date was April 22, 2025), and that the 503B period ended May 22, 2025.
The FDA has posted later updates to this policy, most recently dated April 1, 2026; check the FDA page for the current statement[1]. Once a drug comes off the shortage list, the shortage basis for compounding copies of it no longer applies in the same way.
Compounded GLP-1 availability may change as the regulatory environment evolves. This is not a hypothetical risk. The FDA says it has issued warning letters to stop online distribution of illegally marketed semaglutide and tirzepatide, and has warned telehealth companies about how they market unapproved GLP-1 drugs[2].
What compounded GLP-1 medications are and are not
What they are:
Compounded semaglutide and tirzepatide are preparations made by licensed compounding pharmacies using active pharmaceutical ingredients (APIs), which should come from FDA-registered suppliers. They are prepared in controlled settings and, at reputable pharmacies, undergo batch testing to verify potency and purity.
A prescription from a licensed healthcare provider is required. A licensed provider evaluates the patient’s health history and decides whether a compounded GLP-1 medication is clinically appropriate. If it is, the prescription is sent to the compounding pharmacy.
What they are not:
Compounded semaglutide and tirzepatide are not FDA-approved drugs. They have not gone through the FDA’s drug approval process, which evaluates a specific manufacturer’s specific formulation for safety, efficacy, and quality. They are not generics. Generic drugs are FDA-approved products that go through an Abbreviated New Drug Application (ANDA) process. Compounded drugs do not go through that process.
Compounded versions should not be described as equivalent to, identical to, or interchangeable with brand-name versions. The active pharmaceutical ingredient may be the same compound, but the formulation, excipients, sterility testing, stability data, and manufacturing controls differ. This is why describing a compounded product as equivalent to a brand-name product is misleading.
If your real question is whether these medications produce results, we cover what the clinical evidence shows for each molecule, and how compounded versions relate to that evidence, in does compounded semaglutide work and does compounded tirzepatide work.
Quality indicators: what to look for in a compounding pharmacy
Quality in compounding pharmacy practice is real and verifiable, but it is not uniform. Here is what to look for:
State pharmacy board license. Every compounding pharmacy should hold an active license in the state where it operates. You can verify this through the state pharmacy board website. A license should be current, not expired or under disciplinary action.
PCAB accreditation. The Pharmacy Compounding Accreditation Board (PCAB) is an independent accreditation body that evaluates compounding pharmacies against standards for quality and safety. PCAB accreditation is voluntary, but it is one of the main independent quality signals available for 503A compounders. Not all pharmacies are accredited; those that are have elected to undergo external review.
Certificate of analysis (COA) for each batch. A reputable compounding pharmacy performs testing on each batch of compounded medication to verify that it contains the stated active ingredient at the stated potency, and that it meets sterility and purity standards. This testing is often done by an independent third-party laboratory. A COA documents those results. You can ask to see the COA for your medication lot. If a pharmacy cannot or will not provide one, that is a red flag.
FDA inspection history. For 503B outsourcing facilities, FDA inspection records are publicly available. You can search the FDA database for inspection results, 483 observations (documented deficiencies found during inspections), and warning letters. A clean inspection history, or responsiveness to any identified issues, indicates a pharmacy that takes quality seriously.
Clean regulatory history. Check whether the pharmacy has received FDA warning letters, state board disciplinary actions, or adverse event reports related to its compounded products.
Ask any program you are considering which pharmacy prepares its medication. A program that will not name its pharmacy, or a pharmacy that cannot produce batch-level testing documentation, is a reason to keep looking.
The post-shortage picture: what 2025-2026 means for compounded GLP-1
The removal of semaglutide and tirzepatide from the FDA shortage list changed the legal landscape for GLP-1 compounding in ways that are still being sorted out.
The FDA’s position is that the shortage-based room to compound copies of these medications ended with the shortages, and its stated enforcement-discretion periods for 503A pharmacies and 503B outsourcing facilities ended in 2025[1]. The FDA has also sent warning letters about how compounded and unapproved GLP-1 drugs are sold and marketed[2].
This does not mean all compounded GLP-1 medications immediately became unavailable or illegal overnight. The legal picture is more complicated than that. Some pharmacies and programs say compounding can continue in certain patient-specific situations, for example when a prescriber determines that a patient needs a change from the approved product. Courts and administrative proceedings have been working through some of these questions.
What it does mean: the availability of compounded GLP-1 medications is not guaranteed to continue, and any company that represents otherwise is not being accurate. If you are planning longer-term treatment, ask the provider you choose what would happen if the compounded option became unavailable.
For an updated summary of compounding rules post-shortage, see: Compounded GLP-1 after the shortage.
What to check before using compounded GLP-1 medication
Transformation Health is an independent guide. It does not prescribe, compound, sell, or ship medication, and it does not work with pharmacies.
At most telehealth programs, a licensed provider reviews your health history and decides whether a compounded GLP-1 medication is appropriate before any medication is dispensed. That clinical decision rests with the provider. Before you choose a program, ask which pharmacy prepares the medication, whether it is a 503A pharmacy or a 503B outsourcing facility, and where it is licensed, then check that pharmacy against the quality indicators above.
For a checklist, see how to choose a safe compounding pharmacy. If you are comparing telehealth programs and want the criteria that separate a legitimate one from a risky one, see how to choose a compounded GLP-1 provider.
Transformation Health does not accept payment from providers. How we make money.
What a compounded GLP-1 program costs
Prices vary by program and dose. Transformation Health does not sell medication or set prices. We plan to publish current market prices with sources and capture dates; until then, compare the total cost of any program you are considering: medication at your likely dose, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms.
If you are comparing the lowest advertised prices you have seen, read the cost of compounded semaglutide and compounded tirzepatide cost breakdowns first. The lowest headline number is often not the monthly total once consultation fees, labs, and shipping are added back in.
What’s in this section
This section covers compounded GLP-1 medications, from how programs work to the regulatory and safety background.
Getting started with a compounded GLP-1 program
How to get compounded semaglutide online - The step-by-step path to a legitimate prescription through licensed telehealth, what providers usually look at, and what drives the cost.
How to get compounded tirzepatide online - The same process for tirzepatide, which is usually offered as an injection.
Compounded oral semaglutide - The needle-free daily option, how it differs from the weekly injection, and what to ask about it.
Compounded GLP-1 without insurance - How cash-pay pricing works, what a monthly fee may cover, and why no prior authorization is needed.
Compounded GLP-1 delivery and subscription - How the medication usually ships, what monthly programs may include, and how refills and renewals work.
How to choose a compounded GLP-1 provider - The objective criteria that separate a legitimate telehealth program from a risky one, and the red flags to avoid.
Is compounded semaglutide legit? - How to tell a legitimate provider from an unsafe source, and what the law actually says.
Does compounded semaglutide work? - What the clinical evidence for semaglutide shows, and how compounded versions relate to it.
Does compounded tirzepatide work? - The same question for tirzepatide, with the SURMOUNT-1 trial evidence and the compounded distinction.
Is compounded GLP-1 still available in 2026? - The current availability picture after the shortage ended, and what to do now.
Switching from brand-name to compounded - What a switch from a brand-name GLP-1 to a compounded medication involves, and how a provider handles your dose.
Understanding compounded medications
Compounded tirzepatide: legal status, safety, cost - What compounded tirzepatide is, where it stands legally after the shortage, and how its cost compares to the brand-name version.
Is compounded semaglutide safe - A detailed look at the safety evidence, what FDA has said, and how to evaluate risk for yourself.
503A vs. 503B compounding pharmacies - A clear explanation of the two regulatory categories, what each means for quality standards, and why the distinction matters.
Cost of compounded semaglutide - What drives the price, what a monthly fee may or may not include, and how to compare total cost.
Compounded tirzepatide cost - What a compounded tirzepatide fee may cover and how to read the price variation you see online.
How to choose a safe compounding pharmacy - A practical checklist for verifying a pharmacy’s legitimacy before you fill a prescription there.
How to vet a compounding pharmacy - A 10-point checklist: licenses, inspection history, testing, ingredient source, labels, shipping, and reviews.
GLP-1 recalls and safety alerts: FDA data - A running summary of FDA recall actions, safety alerts, and warning letters related to compounded GLP-1 medications.
Compounded GLP-1 after the shortage - What the removal of semaglutide and tirzepatide from the FDA shortage list means for the legality and availability of compounded versions.
Back to the GLP-1 cost and pricing overview.
What to do if you are evaluating this option
If you are considering a compounded GLP-1 medication, the starting point is an evaluation by a licensed provider who can review your health history and decide whether it is clinically appropriate for you. At most telehealth programs, that review happens before any prescription is written.
Before you choose a program, compare what each one covers, which pharmacy it uses, and its cancellation terms. The guides above walk through each of those checks.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16.)
[2] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16.)
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality[2]. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency. Results vary. Trial results describe study participants and are not a prediction for any individual. Availability of compounded GLP-1 medications depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Transformation Health does not accept payment from providers. How we make money.